基本信息
views: 118
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dae Yoon Chi was born in Pusan, Korea, in 1955. He received a BS in chemistry from Sogang University (1977) and continued for his MS studies from KAIST in organic chemistry with Professor Sang Chul Shim (1979) and for his Ph.D. studies from the University of Illinois at Urbana-Champaign (UIUC) in organic chemistry with Professor John A. Katzenellenbogen (1986). He did his postdoctoral work with Professors John E. Hearst and Henry Rapoport at the University of California, Berkeley (1986-88) and joined at KIST. In 1992, he moved to UIUC as a visiting scientist (1992-94). Then he was appointed staff member of the Department of Nuclear Medicine, Samsung Medical Center for a year and a half. In 1995, he was appointed associate professor at the Department of Chemistry, Inha University, and promoted to professor in 2000. In 2009, he moved to the Department of Chemistry, Sogang University. Meanwhile, he founded FutureChem Co., Ltd. (KOSDAQ stock market, 2016) in 1999 and serves until now as a CEO to serve the radiochemistry researchers by supplying radiopharmaceutical precursors since 1999. He was also appointed Invited Professor, Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea (2002) as well as Adjunct Professor of Asan Medical Center, Seoul, Korea (2010). He served as a chairman of the 20th International Symposium on Radiopharmaceuticals and Sciences which will be held at Jeju Island, May 12-17, 2013. Dr. Chi's research spans organic chemistry, medicine, and PET and SPECT radiopharmaceutical chemistry. He developed many methods for the preparation of radiopharmaceuticals: Halofluorination of F-18 (with Prof. John A. Katzenellenbogen) and Integrated method for Tc-99m (with JAK), F-18 Fluorination in ionic liquid, and F-18 labeling in protic solvent (Chi’s method). Especially, Chi’s method shows the mass production of F-18 labeled radiopharmaceuticals in an aliphatic position. This method made a possibility to register and be used now two new radiopharmaceuticals – F-18 FLT and F-18 FP-CIT (PDvue®) – from the Korean FDA. These are the first registered PET radiopharmaceuticals officially used after FDG through the clinical trials. He registered F-18 Alzheimer imaging agent florapronol (Alzavue®) from the Korean FDA on Feb. 2, 2018. Recently, he found both diagnostic and therapeutic drugs for prostate cancer – FC303 (Florastamin, Prostavue®, in 5 hospitals clinical trial phase 3 in Korea) and FC705 (Ludotadipep, Prosluthera®, in clinical trial phase 1 in Korea and the United States). The latter therapeutic drug is based on PRRT (Protein Receptor Radionuclide Therapy).He spent all his carrier developing methodologies of fluorine-18 and technetium-99m since 1982. He also attended most of the ISRS meetings. He collaborates extensively with other researchers in Korea and internationally. He published around 210 scientific papers, 7 book chapters and filed more than 100 patents. After he retired from Sogang University, Department of Chemistry on Aug. 31, 2020, he is actively working as the CEO of three companies. As his company has a Research Institute of Labeling, he can do radiopharmaceutical chemistry continuously.
Research Interests
Papers共 378 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Korean journal of radiologyno. 2 (2024): 179-188
Jae Hun Ahn,Min Hwan Kim,Kyongkyu Lee,Keumrok Oh,Hyunwoo Lim,Hee Seup Kil, Soon Jeong Kwon,Jae Yong Choi,Dae Yoon Chi, Yong Jin Lee
Prostate Internationalno. 1 (2023): 40-45
Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Chul Hee Kim, Hee Seup Kil, Yong Jin Lee, Kyo Chul Lee,Dae Yoon Chi
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023): 107-113
NUCLEAR MEDICINE AND BIOLOGY (2023): S195-S195
Cited0Views0Bibtex
0
0
Nuclear Medicine and Biology (2023): 108648
Load More
Author Statistics
#Papers: 384
#Citation: 8072
H-Index: 46
G-Index: 75
Sociability: 7
Diversity: 3
Activity: 23
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn